Literature DB >> 989965

Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection.

E A Johnson, T B Kirkwood, Y Stirling, J L Perez-Requejo, G I Ingram, D R Bangham, M Brozović.   

Abstract

Four different heparin preparations--sodium and calcium salts of the same batch of heparin (mean molecular weight 15,000), low molecular weight sodium heparin (mean m.w. 9,000) and high molecular weight sodium heparin (mean m.w. 22,000) were injected subcutaneously on different days each into 6 healthy young volunteers in a randomized trial. Plasma heparin levels were measured using the anti-Xa assay at 1 hour, 3-4 hours and 6-7 hours after the injection. The highest anti-Xa potentiating effect was obtained after the injection of the low molecular weight sodium heparin (mean 0.381 i.u./ml) at 3-4 hours after the injection. With sodium heparin (m.w. 15,000) the highest values (0.135 i.u./ml) were found at 1 hour. Significantly lower anti-Xa potentiating effect was obtained 1 hour after the injection of calcium heparin and in particular after the injection of high molecular weight heparin (mean values 0.072 i. u./ml and 0.043 i. u./ml respectively). Both these preparations showed an increase from 1 hour after injection to 3-4 hours after injection (mean values 0.082 i. u./ml and 0.057 i. u./ml at 3-4 hours after injection). These results indicate that the salt and the molecular weight of the preparation may strongly influence the degree of anticoagulation achieved after subcutaneous injection.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 989965

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

Review 1.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  The current status of low-dose heparin in the prophylaxis of thrombophlebitis and pulmonary embolism.

Authors:  V V Kakkar
Journal:  World J Surg       Date:  1978-01       Impact factor: 3.352

Review 3.  Engineering of routes to heparin and related polysaccharides.

Authors:  Ujjwal Bhaskar; Eric Sterner; Anne Marie Hickey; Akihiro Onishi; Fuming Zhang; Jonathan S Dordick; Robert J Linhardt
Journal:  Appl Microbiol Biotechnol       Date:  2011-11-03       Impact factor: 4.813

Review 4.  Prophylaxis of venous thromboembolism.

Authors:  V V Kakkar; M D Stringer
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

5.  A prospective randomized trial of low molecular weight heparin-DHE and conventional heparin-DHE (with acenocoumarol) in patients undergoing gynaecological surgery.

Authors:  R A Steiner; K Keller; T Lüscher; W E Schreiner
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

6.  Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis.

Authors:  U Schmitz-Huebner; H Bünte; G Freise; B Reers; C Rüschemeyer; R Scherer; H Schulte; J van de Loo
Journal:  Klin Wochenschr       Date:  1984-04-16

Review 7.  The design and synthesis of new synthetic low-molecular-weight heparins.

Authors:  K Chandarajoti; J Liu; R Pawlinski
Journal:  J Thromb Haemost       Date:  2016-04-15       Impact factor: 5.824

8.  Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis.

Authors:  V V Kakkar; B Djazaeri; J Fok; M Fletcher; M F Scully; J Westwick
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-06

Review 9.  Clinical pharmacokinetics of heparin.

Authors:  J W Estes
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

Review 10.  Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.

Authors:  S Noble; D H Peters; K L Goa
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.